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SUMMARY
Objective: EpiNet was established to encourage epilepsy research. EpiNet is used for
multicenter cohort studies and investigator-led trials. Physicians must be accredited
to recruit patients into trials. Here, we describe the accreditation process for the
EpiNet-First trials.
Methods: Physicians with an interest in epilepsy were invited to assess 30 case sce-
narios to determine the following: whether patients have epilepsy; the nature of
the seizures (generalized, focal); and the etiology. Information was presented in
two steps for 23 cases. The EpiNet steering committee determined that 21 cases
had epilepsy. The steering committee determined by consensus which responses
were acceptable for each case. We chose a subset of 18 cases to accredit investiga-
tors for the EpiNet-First trials. We initially focused on 12 cases; to be accredited,
investigators could not diagnose epilepsy in any case that the steering committee
determined did not have epilepsy. If investigators were not accredited after assess-
ing 12 cases, 6 further cases were considered. When assessing the 18 cases, investi-
gators could be accredited if they diagnosed one of six nonepilepsy patients as
having possible epilepsy but could make no other false-positive errors and could
make only one error regarding seizure classification.
Results: Between December 2013 and December 2014, 189 physicians assessed the 30
cases. Agreement with the steering committee regarding the diagnosis at step 1 ran-
ged from 47% to 100%, and improved when information regarding tests was provided
at step 2. One hundred five of the 189 physicians (55%) were accredited for the EpiNet-
First trials. The kappa value for diagnosis of epilepsy across all 30 cases for accredited
physicians was 0.70.
Significance: We have established criteria for accrediting physicians using EpiNet.
New investigators can be accredited by assessing 18 case scenarios. We encourage
physicians with an interest in epilepsy to become EpiNet-accredited and to participate
in these investigator-led clinical trials.
KEYWORDS: Clinical trials, Diagnostic accuracy, Accreditation, Multicenter collabo-
ration.
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Introduction
Epilepsy is a common but complex disease with multiple
subtypes. Although it is a global disease, the incidence, eti-
ology, and outcomes of epilepsy vary among countries.1
Much regarding the pathogenesis and management of epi-
lepsy, and detail of geographic variation, is still unknown.
The investigation of rare forms of epilepsy requires the
involvement of multiple centers to gain sufficiently large
cohorts. Despite this, relatively few patients participate in
research. Knowledge of epilepsy management is mostly
derived from studies conducted in high-income countries;
resource-poor areas are seldom included, although most
people with epilepsy live in these regions.2 There is a great
need to involve epilepsy experts from developing countries
in research projects.
The efficacy and tolerability profiles of antiepileptic
drugs (AEDs) are generally based on trials of short duration
performed in highly selected patient groups.3 The relative
merits of these drugs have not been well established, and
there is little evidence to guide clinicians when the first
AED fails, or to direct combination therapy when monother-
apy is ineffective. The precise indications for nonpharma-
ceutical therapy, including diet, vagal nerve and deep brain
stimulation, and surgery, still need to be determined.
When doctors do not know the best treatment for a
patient, they should endeavor to find out; this involves
accessing evidence-based guidelines, reviewing the litera-
ture, and consulting experts. We contend that if there is no
evidence to guide therapy, then doctors should encourage
patients to participate in trials in which different treatments
are compared (comparative effectiveness research).
Barriers to participation in research
Many clinicians do not consider research to be part of
their job. They are responsible for the care of the patients in
clinics or hospital wards, but they may consider that
research is for academics. Even if clinicians are interested
in research, they are often too busy to participate. Most
health services are under considerable financial pressures,
and many physicians work long hours and struggle to cope
with the clinical demands. Many health services do not
encourage research. The difficulties of conducting clinical
research while undertaking routine clinical care have
recently been highlighted in the New England Journal of
Medicine. Only 4% of 459 general practices in the United
Kingdom who were approached to participate in a compara-
tive effectiveness trial comparing two statin drugs ever
recruited patients.4,5
Patients can be suspicious of research; they may be con-
cerned that they will be put at risk, or that researchers will
take advantage of them. Time and patience are required to
convince patients that it is in everybody’s interests—partic-
ularly theirs—to find out which treatments are most effec-
tive. Even if the risks from the research are no greater than
those associated with routine clinical care, participation
takes time, and this can leave them financially disadvan-
taged if they are not reimbursed for their visits.
Regulatory barriers need to be overcome. Institutional
review boards and ethics committees have an important role
to protect patients and to ensure that research is of a high
standard. However, this means that even relatively low-risk
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Key Points
• More physicians and patients need to participate in
clinical research so that we can learn more about the
optimal treatment of epilepsy
• The EpiNet study group has been established to facili-
tate multicenter collaborative research studies
• The diagnosis of epilepsy and specific seizure types
often involves uncertainty, and this needs to be
acknowledged
• Formal accreditation processes should be undertaken
to confirm that investigators participating in trials use
similar diagnostic strategies
• The EpiNet study group has established an accredita-
tion process for investigators participating in the Epi-
Net-First trials
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studies may have to overcome major hurdles before they
commence. Regulatory hurdles are particularly high for
multicenter studies, where multiple ethics committees and
research governance committees need to evaluate a project.
Pharmaceutical companies have the resources to over-
come the regulatory hurdles. They are also able to make
clinical research lucrative for investigators. If researchers
are generously reimbursed for their time, then they may sac-
rifice other activities for research. This is often a mutually
beneficial arrangement; the research gets done according to
a satisfactory time scale, and the investigators may earn
funds that can be used to develop services in their depart-
ments. This research model is effective in ensuring that par-
ticular types of clinical research are performed; however,
the agenda for this research is set by pharmaceutical compa-
nies, which are working under a financial imperative; they
are interested in research studies that will help them market
their particular drug. They are less likely to be interested in
funding research that might not increase their sales, and they
may be wary of comparative studies that might actually
show another drug is more effective than their own. One of
the consequences of the success of this model is that it may
create a mind-set in researchers and healthcare providers
that they should be generously reimbursed for research.
However, we argue strongly that it is in everyone’s interests
to find out what the best treatments are for the many differ-
ent types of epilepsy.
The EpiNet project as a means to undertake research in
clinical practice
The EpiNet project was established in 2009 under the
auspices of the New Zealand chapter of the International
League Against Epilepsy (NZLAE) to try to increase the
proportion of doctors and patients with epilepsy who partici-
pate in comparative effectiveness research.6,7
EpiNet is an online database that is versatile, easy to
use, and comprehensive (www.epinet.co.nz). Information
is collected for a range of axes, including seizure type,
epilepsy syndrome, etiology, investigations, and treatment
history. The database can be accessed by approved inves-
tigators who log on to a secure, password-protected web-
site. The information contained within it is owned by the
individual investigators participating in the EpiNet collab-
oration, and access to the information is controlled by a
steering committee.
An international pilot study was undertaken from
September 2010 to November 2011. Adult and pediatric
neurologists from 13 countries participated. By the end of
November 2011, more than 1,050 patients had been regis-
tered by 55 neurologists or research assistants working in
25 centers in 13 countries.8 All patients gave their
informed consent to have their information stored in the
database.
As of the end of October 2016, over 10,000 patients from
29 countries had been entered into the database.
Because the goal of EpiNet is to integrate research with
clinical practice, the database has also been designed to
function as an electronic clinical epilepsy record for the
patient. The results of a patient’s investigations and the full
drug history are available in a single document. Records can
be shared with other physicians from the patient’s country if
the investigator and patient so wish. Investigators have a
database of their own patients, and each investigator can
download information from their own patients’ records and
analyze these without any permission required of the EpiNet
study group.
The EpiNet steering committee wants the project to be a
grassroots collaboration. We want researchers around the
world to identify research questions and develop research
protocols to answer these questions. Researchers who are
not currently participating in EpiNet are welcome to per-
form trials using this platform. We also want people with
epilepsy to have a major role in directing the research. We
want to run large, simple, pragmatic, investigator-led,
multinational trials and prospective population-based
cohort studies at low cost. We intend to ask questions that
pharmaceutical companies are not asking.
Data quality: EpiNet validation study and accreditation
of investigators
To ensure that research is of high-quality, and that studies
are comparable, investigators must have comparable skills
and exhibit a satisfactory interrater agreement. Data collec-
tion should be performed in a standard way. The EpiNet
database has been designed to collect comprehensive infor-
mation about patients with epilepsy, in a user-friendly but
standardized manner.
The validity of research studies depends on the level of
confidence that those included actually had the condition of
interest. Epilepsy is often a clinical diagnosis, and it is well
recognized that the interrater agreement between clinicians
in the diagnosis and syndromic classification of epilepsy is
only moderate, even between experienced neurologists.9–12
Ongoing education is important. Internal rules and check-
lists can be established within a database to ensure that
patients recruited for studies do meet all the entry criteria,
and an expert panel can review details of patients who might
be eligible for a study before they are recruited. The level of
agreement between investigators can also be improved by
using predefined diagnostic criteria and panel discussion.
The EpiNet steering committee intends to accredit inves-
tigators for particular studies. We envisage multiple levels
of accreditation, which are not necessarily arranged in a
hierarchical manner. Investigators who have a particular
subspecialty interest might be accredited for some studies,
but not others. The EpiNet steering committee will oversee
the accreditation processes but will not necessarily arrange
accreditation for specific studies; these processes may be
determined by the particular study coordinators. Accredita-
tion for one study may require assessing a standardized set
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of case histories or reviewing electroencephalograms
(EEGs); accreditation for another study may be given after
investigators have attended a workshop or may be based on
formal or informal qualifications, such as the International
League Against Epilepsy’s proposed Competencies for
Epileptologists.13
This paper addresses the processes we have developed to
accredit investigators for the first of the multicenter prag-
matic randomized controlled trials that are being undertaken
by the EpiNet study group.
Aims of EpiNet validation study
The EpiNet validation study was undertaken from
December 2013 through 2014. It had two aims: (1) to
accredit investigators for the EpiNet-First trials. These are
randomized controlled trials in patients with previously
untreated epilepsy (details regarding the EpiNet-First trials
are given below and in the discussion); (2) to determine how
much variability there is between neurologists and epilep-
tologists in diagnoses.
This paper addresses accreditation for the EpiNet-First
trials. The EpiNet steering committee wanted to ensure that
all investigators who participate in these trials diagnose epi-
lepsy and seizure types in a consistent way. For practical
purposes, this involves meeting particular criteria deter-
mined by the steering committee. The steering committee
also wanted to establish a process that would allow future
investigators who had not participated in the validation
study to get accredited at a later date without having to
assess the complete set of 30 cases.
A separate paper analyzing levels of agreement
between neurologists and epileptologists is being pre-
pared. This will look at levels of agreement for the entire
sample, for subgroups from differing geographic areas,
and for subgroups determined by levels of specialization
and experience.
Methods
Initially, 40 scenarios of real patients who had paroxys-
mal attacks of various types were prepared by P.B. The six
members of the EpiNet steering committee then indepen-
dently assessed the 40 cases to determine:
(1) How likely it was that each patient had experienced one
or more epileptic seizures; the options presented for
level of confidence of a diagnosis of epilepsy were: cer-
tain (seizure recorded on EEG); beyond reasonable
doubt; probable; possible; unlikely; not epilepsy.
For subsequent analysis, these six options were consoli-
dated into three broader categories: epilepsy (certain,
beyond reasonable doubt, and probable); possible epilepsy;
and not epilepsy (unlikely; not epilepsy).
(2) The nature of the attacks, with seizures categorized by
the ILAE 2010 classification schema14 (focal seizures;
generalized seizures; epileptic seizures, but nature
uncertain; nature of attacks uncertain [possibly epilep-
tic]; attacks not epileptic).
(3) The etiology of the epilepsy, in broad categories, using
the ILAE 2010 classification schema14 (genetic/pre-
sumed genetic; structural/metabolic; unknown; not epi-
lepsy).
After discussion within the steering committee, 10 cases
were excluded, either because they were too similar to other
cases or because more than one of the six members of the
steering committee disagreed with the consensus diagnosis.
The final set of 30 cases chosen for the validation study
included 21 patients with epileptic seizures and 9 with sei-
zure mimics.
The EpiNet steering committee invited neurologists,
epileptologists, and pediatricians who had expressed an
interest in the EpiNet-First trials and other physicians with
an interest in epilepsy to participate in this validation study.
Participants were invited to assess the 30 cases and deter-
mine diagnosis, seizure type, and etiology, as detailed
above, via the online EpiNet database. Twenty-three of the
cases were presented in two steps, with clinical information
in step 1 and results of investigations in step 2. Participants
were required to give their opinions regarding epilepsy
diagnosis, seizure type, and epilepsy etiology after each
step.
The EpiNet steering committee chose a subset of cases
that could be used to accredit investigators for the EpiNet-
First trials.15,16 These trials involve patients with newly
diagnosed epilepsy, and the steering committee therefore
decided that the most important requirement was that inves-
tigators can correctly determine whether patients have
epileptic seizures. The second requirement was that investi-
gators can correctly distinguish focal seizures from general-
ized seizures because there are separate trials for patients
with different seizure types.15,16 Following discussion, the
EpiNet steering committee identified 18 cases to be used for
accreditation for the EpiNet-First trials. Some of the patients
have epilepsy and some have other common paroxysmal
attacks. These cases represent the types of patients who are
commonly seen in first seizure clinics but also include sev-
eral patients with established epilepsy. The steering com-
mittee determined by consensus which responses were
acceptable for these cases. For most cases, a range of
responses was accepted; for instance, if the steering com-
mittee thought the patient clearly has epilepsy, then only the
options “certain,” “beyond reasonable doubt,” or “probable”
were accepted; if any members of the steering committee
considered that there was diagnostic uncertainty, then the
“possible” option was also considered acceptable. The steer-
ing committee took the approach that it is better to err on the
side of not including in trials some people who might actu-
ally have epilepsy than to include people who do not have
epilepsy.
When accrediting individual investigators, we initially
focused on a subset of 12 cases. To be accredited,
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investigators could not diagnose epilepsy (“certain,” “be-
yond reasonable doubt,” or “probable”) in any of the cases
that the steering committee had determined did not have
epilepsy, but they could diagnose one of the epilepsy cases
as not having epilepsy (“unlikely” or “not epilepsy”). Inves-
tigators could not diagnose generalized seizures in cases the
steering committee determined had focal seizures, and vice
versa; however, the option “epileptic seizures, but nature
uncertain” was considered acceptable in some cases. If
investigators made an error with 1 of the initial 12 cases, the
final 6 of the 18 cases were reviewed. When assessing the
full 18 cases, investigators could be accredited if they diag-
nosed 1 of 6 nonepilepsy patients as having possible epi-
lepsy but made no other false-positive errors in diagnosis,
and they could make no more than one error regarding sei-
zure classification.
Investigators’ responses on the etiology form were not
considered in the accreditation process.
We have included as supporting information the 12 cases
that were not used for the accreditation process; these
demonstrate the type of material that is included in the case
scenarios. We have not included the 18 cases that were actu-
ally used to accredit investigators because the same cases
are still being used to accredit new investigators.
We calculated kappa values to look at the levels of agree-
ment among all participants and separately for those who
were accredited for the EpiNet-First trials. The kappa statis-
tic is a measure of agreement that is corrected for the level
of agreement that would be expected to occur by chance
alone. It is calculated as the proportion of agreement beyond
that expected by chance (the achieved beyond chance agree-
ment as a proportion of the attainable beyond chance agree-
ment). Kappa values range from 1 to 1. According to
Landis and Koch, kappa values can be classified as poor
(less than chance—kappa below 0), slight (0.01–0.20), fair
(0.21–0.40), moderate (0.41–0.60), substantial (0.61– 0.80),
and almost perfect agreement (0.81–1.00).17
Results
One hundred eighty-nine physicians from 36 countries
assessed the 30 cases. The distribution of responses for these
189 physicians for each of the cases is shown in Tables 1–3.
Of the 21 cases that the steering committee determined
had epilepsy, agreement with the steering committee
regarding the diagnosis at step 1 ranged from 47% to 100%
(Table 1). The mean percentage of investigators who diag-
nosed epilepsy for the 21 cases at step 1 was 83%. For the
18 cases where information was provided in two steps, the
mean percentage of investigators who diagnosed epilepsy
increased from 85% to 90% after step 2.
Of the 9 cases that the steering committee determined did
not have epilepsy, agreement among participants with the
steering committee at step 1 ranged from 47% to 92%. The
mean percentage of investigators who diagnosed “not
epilepsy” for the 9 cases at step 1 was 72%. For the 5 cases
where information was provided in two steps, the mean per-
centage of investigators who diagnosed “not epilepsy”
increased from 72% to 79% after step 2.
The responses for seizure types are shown in Table 2.
The steering committee considered that 9 of the patients had
generalized seizures; the mean proportion of participants
who diagnosed generalized seizures for these 9 cases at step
1 was 67%, increasing to 80% at step 2. The steering com-
mittee considered that 11 patients had focal seizures; the
mean proportion of participants who diagnosed focal sei-
zures for these 11 cases at step 1 was 67%. For the 9 cases
where information was provided in two steps, the mean per-
centage of investigators who diagnosed focal seizures at
step 1 was 63%, increasing to 75% at step 2.
The responses for etiology are shown in Table 3. Of the 8
cases that the steering committee determined had a genetic
etiology for their epilepsy, agreement with the steering com-
mittee ranged from 31% to 91% at step 2. The mean propor-
tion of participants who diagnosed a genetic etiology for
these 8 cases at step 1 was 62%, and increased to 74.9% at
step 2.
Of the 4 cases that the steering committee determined had
a structural/metabolic etiology for their epilepsy, agreement
with the steering committee ranged from 72% to 96% at step
1. The mean proportion of participants who diagnosed a
structural/metabolic etiology for these 4 cases at step 2 was
87%.
The EpiNet steering committee was uncertain of the etiol-
ogy in 9 of the patients with epilepsy. The mean proportion
of participants who selected “unknown” for the etiology for
these 8 cases was only 48% at step 1. After step 2, 56% of
participants selected “unknown” for the etiology.
Accreditation criteria
When we focused on the 18 cases that the steering com-
mittee determined should be used for accreditation, 105
(55.6%) of the 189 physicians who assessed all 30 cases in
the EpiNet validation study met the standard for accredita-
tion.
The kappa value for the diagnosis of epilepsy at step 1 for
all 189 participants who completed the 30 cases was moder-
ately good, at 0.60, although it was only fair for seizure type
(0.39) and etiology (0.38). For the 105 physicians who met
the criteria for accreditation when assessing the subset of 18
cases, the kappa value for all 30 cases at step 1 increased to
0.70 for the diagnosis of epilepsy, 0.47 for seizure type, and
0.45 for etiology.
Discussion
The validation study and accreditation process
Many of the patients included in this study had classical
presentations, and we expected most participants to find
assessment of these cases easy. More than 90% of
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participants correctly diagnosed epilepsy in 10 of the 21 epi-
lepsy cases, and all 189 participants correctly diagnosed epi-
lepsy in case 4. However, we also deliberately included
several “gray cases.” This was done to determine how par-
ticipants manage diagnostic uncertainty because most
physicians see patients where there is genuine uncertainty
regarding the diagnosis. Practicing clinicians sometimes
decide that it is appropriate to treat these patients, but
including people who do not actually have epilepsy in trials
of epilepsy treatment will increase the “noise” and reduce
the power of the trials. If these patients are randomized, then
potential bias will be minimized because similar patients
will end up in all arms of a trial. The effect of the added
noise can be reduced by increasing the number of patients
recruited to the trial; however, this adds considerably to the
cost and time taken to complete the study, and trials may
still be underpowered if too many patients who do not have
epilepsy are included. It is probably impossible to com-
pletely exclude all such patients from research studies, but
efforts need to be taken to minimize the number of people
who do not have epilepsy who are recruited into trials.
Patients in whom there is a high level of diagnostic uncer-
tainty should not be recruited into clinical trials.
We have not given details of the specific cases that were
used for accreditation, nor the exact criteria. This is because
we intend to use these cases for accrediting new investiga-
tors. We believe that an accreditation process is required for
diagnostic rigor, though we are also aware that this process
may be challenging to potential investigators; however, we
believe that it is important for the integrity of the trials that a
formal accreditation process is established.
We have undertaken the validation study and accredita-
tion process to reassure the EpiNet study group and the
wider epilepsy community that investigators who recruit
patients for the trials can accurately diagnose epilepsy and
the seizure type under investigation. The steering committee
comprises adult and pediatric neurologists and epileptolo-
gists from five different countries and three continents. We
Table 1. Likelihood of epilepsy (189 participants)
Step 1 Step 2
Epilepsy Possible epilepsy Not epilepsy Epilepsy Possible epilepsy Not epilepsy
Epilepsy cases
1 169 (90.4) 11 (5.9) 7 (3.7) 176 (94.1) 7 (3.7) 4 (2.1)
3 179 (94.7) 6 (3.2) 4 (2.1) 180 (95.2) 5 (2.7) 4 (2.1)
4 189 (100) 0 (0.0) 0 (0.0) 189 (100) 0 (0.0) 0 (0.0)
5 123 (65.4) 38 (20.2) 27 (14.4) 115 (61.2) 40 (21.3) 33 (17.6)
8 186 (99.5) 1 (0.5) 0 (0.0) 187 (100) 0 (0.0) 0 (0.0)
9 88 (46.8) 61 (32.5) 39 (20.7) 145 (77.1) 34 (18.1) 9 (4.8)
10 107 (56.6) 55 (29.1) 27 (14.3) 135 (71.4) 31 (16.4) 23 (12.2)
11 186 (98.9) 2 (1.1) 0 (0.0) 186 (98.9) 2 (1.1) 0 (0.0)
13 165 (87.8) 18 (9.6) 5 (2.7) 179 (95.2) 7 (3.7) 2 (1.1)
14 135 (87.7) 18 (11.7) 1 (0.7) NA NA NA
15 183 (96.8) 4 (2.1) 2 (1.1) 186 (98.4) 2 (1.1) 1 (0.5)
17 186 (98.9) 1 (0.5) 1 (0.5) 186 (98.9) 1 (0.5) 1 (0.5)
18 119 (62.9) 47 (24.9) 23 (12.2) NA NA NA
20 174 (92.1) 14 (7.4) 1 (0.5) 183 (96.8) 5 (2.6) 1 (0.5)
22 135 (72.9) 18 (9.6) 34 (18.2) 174 (93.1) 9 (4.8) 4 (2.1)
23 159 (84.1) 22 (11.6) 8 (4.2) 160 (84.7) 21 (11.1) 8 (4.2)
24 131 (69.3) 25 (13.2) 33 (17.5) 150 (79.4) 16 (8.5) 23 (12.2)
26 117 (61.9) 48 (25.4) 24 (12.7) 171 (90.5) 15 (7.9) 3 (1.6)
28 174 (92.1) 15 (7.9) 0 (0) 186 (98.4) 3 (1.6) 0 (0.0)
29 184 (97.4) 2 (1.1) 3 (1.6) NA NA NA
30 151 (79.9) 31 (16.4) 7 (3.7) 173 (91.5) 14 (7.4) 2 (1.1)
Not epilepsy cases
2 11 (5.8) 25 (13.2) 153 (80.9) 8 (4.2) 24 (12.7) 157 (83.1)
6 32 (17.0) 50 (26.6) 106 (56.4) 14 (7.5) 28 (14.9) 146 (77.7)
7 12 (6.4) 29 (15.3) 148 (78.3) 13 (6.9) 29 (15.3) 147 (77.8)
12 16 (8.5) 26 (13.8) 147 (77.8) NA NA NA
16 23 (12.2) 30 (15.9) 136 (72.0) 20 (10.6) 30 (15.9) 139 (73.5)
19 23 (12.2) 38 (20.1) 128 (67.7) NA NA NA
21 27 (14.4) 73 (38.8) 88 (46.8) NA NA NA
25 23 (12.2) 29 (15.3) 137 (72.5) 10 (5.3) 20 (10.6) 159 (84.1)
27 10 (5.3) 7 (3.7) 174 (92.1) NA NA NA
NA, not available.
Table showing the number of investigators who chose a particular option for the likelihood that each patient had epileptic seizures. Percentages are shown in
italics in parentheses. The cases are separated into epilepsy and not-epilepsy cases as determined by the EpiNet steering committee.
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cannot be certain that the diagnoses made by members of
the steering committee for the validation study are correct,
though we believe that they are. Relatively few of the
patients had diagnostic video-EEG monitoring, which we
would consider the gold standard for epilepsy diagnosis. At
the very least, the accreditation process ensures that all
those participating in the EpiNet-First trials have a similar
approach to diagnosis of epilepsy and epileptic seizures.
The physicians accredited for the EpiNet-First trials had a
high level of interrater agreement (k = 0.70). This is a
higher level of agreement than the interrater agreement
between pediatric epileptologists in a study of the reliability
of diagnoses of first seizures in children (k = 0.41),12 and
neurologists in adult studies of the diagnosis of first seizures
(k = 0.58),9 and the diagnosis of syncope versus seizure
(k = 0.4).10 The higher kappa value seen in our validation
study may be due to the expertise of assessors and differ-
ences in case selection. Although most of our cases had
experienced few attacks, there were several cases with a
longer history. In the pediatric study,12 although the assess-
ing panels comprised epileptologists, the study was
enriched for cases in which there was a high degree of diag-
nostic uncertainty. Both adult studies cited9,12 were
prospective studies, with an unselected case mix.
Studies under way using EpiNet
Randomized controlled trials within EpiNet
The EpiNet-First trials commenced in New Zealand in
late 2015.15,16 These are pragmatic, unblinded, randomized
controlled trials in patients with previously untreated epi-
lepsy. Patients who have had two or more seizures, and who
have not previously received AEDs, are randomized to one
of four AEDs. Five separate trials are being run in parallel.
The specific drugs included in each trial depend on the
patient’s seizure type and the suitability of sodium val-
proate; patients with focal seizures are randomized to leve-
tiracetam, carbamazepine, or lamotrigine (Trial 1). Patients
with generalized seizures are randomized to levetiracetam
or sodium valproate if valproate is deemed a suitable drug
(Trial 2); if valproate is not considered suitable (e.g., in
women of child-bearing age), then patients with generalized
seizures are randomized to receive either levetiracetam or
lamotrigine (Trial 3). If the investigator is uncertain of the
seizure type, then patients are randomized to receive either
levetiracetam, sodium valproate, or lamotrigine (Trial 4) or,
if valproate is not considered suitable, to either levetirac-
etam or lamotrigine (Trial 5).
The EpiNet-First trials are based closely on the SANAD-
ll trials.18 The SANAD-ll (Standard and New Anti-Epileptic
Drugs) trials are unblinded pragmatic trials being conducted
in the United Kingdom in which patients with newly diag-
nosed epilepsy, who have not previously been treated with
AEDs, are randomized to receive either sodium valproate or
lamotrigine (“standard AEDs”) or levetiracetam or zon-
isamide (“newer AEDs”). The standard drugs to which the
newer drugs are being compared are the drugs that were
deemed most effective in the SANAD-l studies.19,20
The EpiNet-First trials have been registered on the Aus-
tralia and New Zealand Clinical Trials registry, and patients
are currently being recruited. We encourage physicians
worldwide to join these trials. Physicians can participate in
one, some, or all of the trials. Formal approval from each
center’s institutional review board or research governance
committee and ethics committee is required before physi-
cians can participate. The coordinating center in Auckland
is happy to help individual physicians obtain approval for
these trials. Investigators are not being paid to enter patients
into these trials.
EpiNet registries
Registries have been established within EpiNet to collect
prospective data on patients who have had a first seizure or
are discontinuing treatment. There is also a registry for
patients who start a first AED who do not get recruited into
one of the EpiNet-First trials. Investigators are encouraged
to systematically record information in these registries of all
eligible patients they see. Proposals for new registries are
welcome.
Future directions
The database has evolved as we have received feedback
from users. It has now reached a considerable level of
sophistication. A large amount of information regarding
patients and their seizures can be collected; however, it is
not necessary to collect all this information on all patients,
and some questions only appear in particular contexts.
New forms can be added to the database to capture infor-
mation regarding different aspects of epilepsy. A form to
collect information relating to status epilepticus has recently
been released, and any EpiNet investigator can use it. Any-
one with an interest in a particular type of epilepsy or treat-
ment modality is welcome to propose a study and to help
with development of the required forms.
Investigators are welcome to enter information on all
their patients or to participate in single studies if they wish.
Although the platform has been established to encourage
multicenter studies, it is also possible to run studies that are
restricted to a particular institution or country. EpiNet is
suitable to establish a registry to determine the outcome
associated with the introduction of a new AED in a particu-
lar country or region. The database can be used to collect
information required for epidemiological studies.
We believe that using an Internet-based platform such as
EpiNet might be the only way in which sufficient data can
be gained regarding outcomes in rare syndromes or when
the outcome itself is relatively uncommon, such as sudden
unexpected death in epilepsy (SUDEP).
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Conclusion
We encourage physicians to participate in comparative
effectiveness research studies. EpiNet has been designed as
a platform to undertake clinical research in epilepsy at rela-
tively low cost. EpiNet is available to all specialist physi-
cians who treat people with epilepsy. Physicians are invited
to participate in the formal registries and record in a system-
atic manner the treatments they institute and the outcomes
of treatment. Physicians are also invited to participate in
simple pragmatic clinical trials and to propose new trials
that could be undertaken using this platform; the EpiNet-
First trials are now under way, and we are looking for new
investigators for these studies. In an effort to ensure appro-
priate patients are enrolled in the trials, physicians need to
be accredited for these trials. We see the accreditation pro-
cess as a way of raising standards and would therefore
encourage physicians to get accredited and to participate in
these trials (http://epinet.co.nz/index.cfm?PageID=11).
Neurologists, epileptologists, and people affected by epi-
lepsy who wish to participate in clinical research are invited
to visit the EpiNet website (www.epinet.co.nz) or to contact
the authors.
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1Appendix
Members of the EpiNet study group who completed at least 20 of the
EpiNet validation study cases or who have admitted significant numbers of
patients into the EpiNet database, listed by country and then alphabetically
by family name.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Appendix S1. The 12 cases that were not used for the
accreditation process. These demonstrate the type of mate-
rial that is included in the case scenarios.
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